Category Archives: Sales

Ibrutinib's Breakthrough to Market

FDA’s new Breakthrough Therapies designation sped Pharmacyclics/J&J’s ibrutinib (brand name: Imbruvica) through regulatory review in four months, based on Phase 2 studies. Pricing and access issues, though, may not get resolved so quickly.
Also posted in Biotech, FDA, healthcare, Market Access, Orphan Drugs, pricing, Regulatory, Strategy | Tagged , , , | 7 Comments

PharmExec's Orphan Drug Pipeline Picks

Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years. In the US, private and government payers haven’t yet had the nerve to balk at rare disease drug prices. […]
Also posted in Global, Orphan Drugs, pricing, R&D, Regulatory, Strategy | Tagged | Leave a comment

Belviq's Battle of the Bulge

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September. Perhaps the most significant development in obesity of late is the recognition by payers – […]
Also posted in Advertising, FDA, Global, healthcare, Market Access, Marketing, Patient Communication, People, pricing, Regulatory, Safety, Strategy | Tagged , , , , , , , , , , , , , , | Leave a comment

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Also posted in Guest Blog, healthcare, Legal, Market Access, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , , | 1 Comment

The Sunshine Act Makes for Gloomy Sales Reps

On Café Pharma message boards, the drug industry’s online water cooler, anonymous sales reps are sounding off on the Physician Payment Sunshine Act and its implications for their battered profession. Here’s a selection from a thread that PharmExec came across, edited for spelling, punctuation, and coherence:
Also posted in Advertising, compliance, Marketing, Medical Education, Regulatory, social media | Tagged , , , | 2 Comments
  • Categories

  • Meta